PML/RARA inhibits expression of HSP90 and its target AKT

Maria Liliana Piredda, Girish Gaur, Gianfranco Catalano, Mariadomenica Divona, Cristina Banella, Serena Travaglini, Maria Carmen Puzzangara, Maria Teresa Voso, Francesco Lo-Coco, Nelida Ines Noguera

Research output: Contribution to journalArticle

Abstract

Essential for cell survival, the 90 kD Heat Shock Proteins (HSP90) are molecular chaperons required for conformational stabilization and trafficking of numerous client proteins. Functional HSP90 is required for the stability of AKT, a serine-threonine kinase phosphorylated in response to growth factor stimulation. AKT plays a crucial regulatory role in differentiation, cell cycle, transcription, translation, metabolism and apoptosis. Acute promyelocytic leukaemia (APL) is characterized by the presence of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARA) fusion protein, which deregulates expression of several genes involved in differentiation and apoptosis. Here, we report inhibition of HSP90AA1 and HSP90AB1 isomer transcription in blasts isolated from patients with APL, associated with reduction of HSP90 protein expression and loss of control on AKT protein phosphorylation. We show that in vitro treatment of PML/RARA expressing cells with all-trans retinoic acid (ATRA) up-regulates HSP90 expression and stabilizes AKT. Addition of the HSP90-inhibitor 17-(allylamino)-17-demethoxygeldanamycin in combination with ATRA, blocks upregulation of AKT protein, indicating that HSP90 is necessary for ATRA action on AKT. This is the first report proving that expression of HSP90 isomers are directly and differentially repressed by PML/RARA, with critical results on cellular homeostasis of target proteins, such as AKT, in APL blasts.

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusAccepted/In press - Jan 1 2018

    Fingerprint

Keywords

  • Acute promyelocytic leukaemia
  • AKT
  • heat shock protein 90
  • HSP90AA1 and HSP90AB1
  • PML/RARA

ASJC Scopus subject areas

  • Hematology

Cite this

Piredda, M. L., Gaur, G., Catalano, G., Divona, M., Banella, C., Travaglini, S., Puzzangara, M. C., Voso, M. T., Lo-Coco, F., & Noguera, N. I. (Accepted/In press). PML/RARA inhibits expression of HSP90 and its target AKT. British Journal of Haematology. https://doi.org/10.1111/bjh.15715